CLOSED
GET A PIECE OF TARGAZYME
The Next Frontier of Cancer Medicine
Show more
REASONS TO INVEST
TEAM
Lynnet Koh • Executive Chairman, CEO, Founder
Read More
Michael Lemaire • Director, Secretary
Read More
Alan Lewis • Director
Read More
Harnessing the power of your immune system to fight cancer
Imagine the next frontier of cancer medicine, where you or your loved ones could potentially be cured by leveraging the power of your own immune system.
With TargaZyme’s novel, patented medicine, cancer-fighting T-cells can be harnessed to eliminate cancer without the harmful side effects and safety issues of current treatments such as chemo, radiation, and radical surgery, many of which only extend life by a few months.
Our novel drugs are patented worldwide and have been validated by renowned medical minds in leading cancer centers in the US. Most important of all, TargaZyme’s treatments have already shown an extremely exciting improvement in patient survival rates after 100 days.
Cancer care is overdue for new advancements, and we believe TargaZyme will be ready to deliver. By removing the pain for cancer patients and improving their prospects for survival and a healthy life, post-cancer, we have the potential to make an enormous difference. We’re committed to developing breakthrough medicine that we hope will have life-changing effects for cancer patients and their families.
TargaZyme is currently pre-revenue and in the R&D stage with our two breakthrough approaches: TZ101, a Phase-3 ready product, and TZ102, which is currently being prepared for clinical or human-patient trials.
The Problem
Current cancer treatments threaten a patient's long-term quality of life
Anyone who’s experienced cancer—whether first-hand or through a loved one—knows that it’s a harrowing, traumatic experience. While modern medicine has brought incredible advancements, we believe the current standard of care for cancer patients remains inadequate.
Current cancer treatments are focused on highly toxic chemotherapy, radiation, radical surgery, or drugs that may extend life by only a few months, often accompanied by major side effects. Chemotherapy is a poison with toxic, life-long side effects that create a long-term impact on a patient's quality of life.
But what if rather than extend a patient’s life by a few months, we could provide a solution that eliminates the disease entirely without the toxic treatments?
Pictured above, from left-to-right: 1.) Cancer cells being attacked by T-cells, 2.) A typical catheter setup that allows for the delivery of medicine and nutrition IV, 3.) Example of cell division (also known as mitosis).
The Solution
Supplanting harmful treatments with cancer immunotherapy
TargaZyme is at the forefront of a breakthrough approach called cancer immunotherapy, which seeks to harness the power of a patient’s own immune system rather than relying on harmful chemotherapy or surgery. Our goal is to cure the patient, not simply treat them, by supercharging the immune system to eliminate the cancer.
Patients with solid tumors could potentially be cured successfully with the patients’ own cancer-fighting T Cells, augmented by our breakthrough drugs, TZ101 and TZ102. This heralds the incredible potential to supplant the use of various toxic cancer therapies, radiation, and radical surgery that make up the current standard of care.
TargaZyme is researching, developing, and working to commercialize enzymes that enhance immune response, whether autologous (from a patient’s own cells) or allogeneic (derived cells).
These enzymes catalyze the body's immune response by directing the cells directly to the disease site. TZ101 and TZ102, delivered to a patient through IV Infusion, enhance the natural mechanism by which circulating cells reach the diseased tissues.
Additionally, they improve the extent and rate of stem cell engraftment while reducing the incidence of life-threatening infections and GvHD. Finally, they increase residence time of anti-inflammatory cells in sites of inflammation, thus significantly reducing patient infection rates compared to historic controls.
In our Phase 2 clinical trials at MD Anderson Cancer Center, a single dose of TZ 101 was shown to improve survival of terminally ill cancer patients from 64% post-100 days of transplant to 78% post-100 days of transplant by preventing various diseases such as infections, GvHD, hemorrhaging, and stem cell engraftment failure.
Equally exciting is that TargaZyme’s enzymes have broad potential utility across all therapeutic categories beyond oncology. We hope to expand the biotechnology to all applicable instances where a patient's body can fight disease with immune responses.
The Market
An early-stage entry point into multiple billion dollar markets
All of TargaZyme’s markets are large, well-defined treatment categories with annual spends in the billions of dollars in the US alone. The cell therapy market was valued at $9.5B in 2021, while the oncology market is projected to reach over $581B by 2030 (source, source).
The COVID-19 pandemic has further emphasized worldwide health challenges, prompting a major shift in healthcare investments and subsequent growth for companies like TargaZyme.
TargaZyme’s closest competitors use methods that are much more time consuming and resource intensive. We have a therapeutic with a production similar to Genzyme (acquired by Sanofi for $20B in 2011; source) in the sense that we are restoring or replacing a recombinant enzyme. However, what makes us unique is our ability to make cures safe, tractable, and expandable across multiple cellular therapeutic types and a variety of diseases.
Historically therapeutics have treated disease, but not provided cures. As our cellular therapy is working to offer patients the possibility of a healthy post-cancer life, there’s understandably excitement about it.
Our Traction
Over 35 patents, $40M in medical awards, and a clear FDA pathway
TargaZyme has received over $40M in prestigious medical awards and has collaborated with great medical minds at leading cancer centers such as MD Anderson Cancer Center, University of Pennsylvania Medical Center, Yale Medical Center, Harvard University Medical School, Duke Medical Center, Oklahoma Medical Research Foundation, and Cleveland Clinic. Our team is extremely proud to have won more competitive medical prizes and published more peer-reviewed medical papers than many of today's publicly listed biotech companies.
We’ve secured over 35 worldwide patents, with over 40 patent-pending applications. As such, TargaZyme has the leading fucosylating-enzyme intellectual-property position, a statement which has been validated by two important third parties of note. One is an independent valuation firm involved in our cross-license with Kyowa Hakko Kirin. The other is multinational biopharmaceutical company, Kyowa Hakko Kirin, itself. Their conclusion was TargaZyme has the pre-eminent position in the space, thus driving their decision to cross-license with TargaZyme.
TargaZyme has been awarded a Phase 3 Special Protocol Assessment by the FDA and has received multiple FDA orphan-drug designations which extend the commercial value of TargaZyme’s Therapies. We’re now in Phase 2 clinical trials, and have a clear FDA pathway towards first approval—which means we’re well on our way to commercializing TargaZyme products.
Funds raised during this campaign will be used towards manufacturing, validating clinical trials towards FDA product approval, worldwide patents, and working capital to support continued momentum towards these key milestones.
Why Invest
A biotech investment towards a life-saving mission
Our conversations with potential investors have proven that biotech is an attractive equity asset class, but too many early-stage companies, including any public companies, are much too far from commercialization to offer the right balance of risk and return. TargaZyme has specifically chosen StartEngine to offer everyday investors the opportunity to join us on the ground floor with an advanced, clinical-stage lead candidate. With early data showing that our products are safe and efficacious in patients, plus support from the FDA that we’re addressing major, unmet medical needs, we believe TargaZyme is the rare, mission-oriented investment opportunity for which many investors have been looking.
By 2030, we plan to be generating multiple revenue streams with major product partnering and licensing, enabling the delivery of cancer cures and further development of multiple additional cures in SCT and autoimmune disease. By 2040, we aim to be one of the leading names in biotech, with a leadership position in cell therapy.
Too many people suffer through cancer and its losses. TargaZyme is ready to create a major legacy as we work towards a cancer-free world.
(or click)
ABOUT
HEADQUARTERS
2100 Palomar Airport Road, Suite 214-219
Carlsbad, CA 92011
WEBSITE
View Site
TERMS
TargaZyme
Overview
PRICE PER SHARE
$6.62
DEADLINE
Sep. 20, 2022 at 6:59 AM UTC
VALUATION
$196.27M
FUNDING GOAL
$10K - $1.07M
Breakdown
MIN INVESTMENT
$595.80
MAX INVESTMENT
$1,069,997.22
MIN NUMBER OF SHARES OFFERED
1,510
MAX NUMBER OF SHARES OFFERED
161,631
OFFERING TYPE
Equity
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Investment Incentives and Bonuses*
Time-Based:
Friends and Family Early Birds
Invest within the first week and receive 10% Bonus Shares
Super Early Bird Bonus
Invest within the first two weeks and receive 8% Bonus Shares
Early Bird Bonus
Invest within the first three weeks and receive 5% Bonus Shares
Amount-Based:
$5,000+
Invest $5,000+ and receive 5% Bonus Shares
$10,000+
Invest $10,000+ and receive 10% Bonus Shares
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
TargaZyme will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $6.62 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $662. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any).
Irregular Use of Proceeds
PRESS
ALL UPDATES
09.19.22
Time is running out
Today is the last day in the Campaign in which to invest in TargaZyme via StartEngine. To date, we have raised $71,778 from 80 investors and we are very appreciative of your commitment to TargaZyme and our mission. Please continue to look for updates on our social media channels including LinkedIn, Facebook and Twitter @TargaZymeBioPharma
Warmest regards,
Tha TargaZyme Team
09.15.22
TargaZyme Campaign Update: Call to Action
TargaZyme is an exciting pre-IPO BioPharma company whose mission is to Cure Cancer through a proprietary patented process harnessing the power of a patient’s own immune system to destroy the cancer. Patients could potentially be cured with the patients’ own cancer-fighting T Cells, augmented by TargaZyme proprietary processing and breakthrough drugs. Upcoming Stage 3 Clinical Trials on path towards FDA approval.
TargaZyme was founded by Lynnet Koh after losing close family members to cancer, she was determined to find a cure. She founded TargaZyme and drove the company to Phase 2 BMT clinical trials at MD Anderson Cancer Center where TargaZyme drugs have been shown to improve cancer patient survival from 64% to 78% post 100 days of transplant.
Informative and brief video about TargaZyme: https://youtube.com/shorts/tTtcwXvPz3k?feature=share
CIO Bulletin just listed Lynnet Koh as one of the "Best Inspiring Leaders of the Year 2022"
https://www.ciobulletin.com/magazine/2022/best-inspiring-leaders-of-the-year-2022
We have raised $10M through private investors and received $40M in Medical Grants & Awards and are now raising capital for our upcoming TZ101/TZ102 Protocol Stage 3 clinical trials.
TargaZyme is unique in that we’ve treatments/protocols for liquid (TZ101) and solid tumor (TZ102) cancers, each at different stages in the clinical trials.
Call to Action: With just 4 days left to invest in Targazyme’s StartEngine Campaign, now is the time to top-up your investment or become an investor before it is too late. So far, we have raised $60,178 from 69 investors, taking us closer to our goal. We are so thankful for all of our investors so far, and look forward to the growth that would not be possible without your investment.
Visit our page at https://www.startengine.com/targazyme to support the next frontier of cancer medicine.
Thank you for your consideration and support.
The TargaZyme Team
09.09.22
We are preparing to close this round of funding.....September 26th
Reasons to Invest in TargaZyme
A single dose of our novel patented medicine TZ101 was shown to improve survival of terminally ill cancer patients from 64% post-100 days of transplant to 78% post-100 days of transplant by preventing various diseases such as infections, GvHD, hemorrhaging, and stem cell engraftment failure in a Phase 2 clinical (human) trial at M D Anderson Center in Texas. Link to TZ101 Patent follows: https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=11&f=G&l=50&co1=AND&d=PTXT&s1=8633021&OS=8633021&RS=8633021
TargaZyme has been awarded over 38 worldwide patents, with over 40 patent-pending applications, and multiple orphan drug awards.
We have received $50m+ in funding to date, of which, $40m+ originated from highly prestigious medical awards. The team has worked with leading medical centers including MD Anderson Cancer Center, University of Pennsylvania Medical Center, Yale Medical Center, Harvard University Medical School, and Cleveland Clinic.
With just days left to invest in Targazyme’s StartEngine Campaign, now is the time to top-up your investment or become an investor before it is too late. So far, we have raised $43,781 from 55 investors, taking us closer to our raise goal. We are so thankful for all of our investors so far, and look forward to the growth that would not be possible without your investment. Visit our page at https://www.startengine.com/targazyme to support the next frontier of cancer medicine.
09.06.22
TargaZyme Video
Learn more about how TargaZyme is curing cancer harnessing the power of the cancer patient's own immune system supercharged by TargaZyme's treatments.
08.26.22
TargaZyme video
Learn more about how TargaZyme is curing cancer harnessing the power of the cancer patient's own immune system supercharged by TargaZyme's treatments.
08.18.22
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the TargaZyme offering. Here's an excerpt describing the specifics of the change:
Issuer is extending campaign end date and updating financial information
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
06.28.22
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the TargaZyme offering. Here's an excerpt describing the specifics of the change:
Issuer is increasing minimum investment amount and removing a D&O.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
REWARDS
10%
Stack Venture Club & Rewards!
Members get an extra 10% shares in addition to rewards below!
Venture Club
Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
$5,000
$5,000+
Invest $5,000+ and receive 5% Bonus Shares
$10,000
$10,000+
Invest $10,000+ and receive 10% Bonus Shares
JOIN THE DISCUSSION
0/2500
W Kim Colich
3 years ago
Hi Lynnet, Now that we are heading into a new month I was looking again at TargaZyme as a possible investment. I am flabbergasted that you INCREASED the minimum investment amount! Why? Raising the bar to $600 is a hurdle many small investors can't jump. They just can't put that many of their limited eggs into one basket, so to speak. Please make your campaign more accessible and inviting to the small investor. Please consider lowering the minimum investment amount back down to your original $304.52, or at least no more than $331.00 (50 shares). Thanks for listening. Blessings
Show more
1
0
Amanda Maldonado
3 years ago
Why was the StartEngine Owner's 10% bonus removed? It is listed in the offering details.
1
0
Prashant Varma
3 years ago
Why aren't you going through the traditional VC funding route instead of crowdfunding? Also, upon reading further on your website I realized that your molecules are not therapies in themselves, they just enhance homing of T cells to the tumor target. The website just talks about TZ102 which means your company relies on just one product (combination of 2 enzymes). Could you talk about where and how you manufacture, the scale of your manufacturing and whether you are thinking of scaling up? Are there other uses besides cancer therapy? Are you working on other enzymes/therapies. How did you arrive at the valuation? I would appreciate concise information on these before thinking about investing. Thank you.
Show more
1
1
Ellen Hanson
3 years ago
Is there any way, if I invest that I could be a participant in the clinic trials for TargaZyme??? This is my current status: 5/17/2022 Clinical Stage Staging form: Corpus Uteri - Carcinoma And Carcinosarcoma, AJCC 8th Edition - Clinical stage from 5/17/2022: FIGO Stage IA (cT1a, cN0(sn), cM0) Histopathologic type: Clear cell adenocarcinoma, NOS Stage prefix: Initial diagnosis Method of lymph node assessment: Sentinel lymph node biopsy Histologic grade (G): G3 Histologic grading system: 3 grade system Depth of myometrial invasion (mm): 5 Pelvic nodal status: Negative Malignant Neoplasm Of Breast Female Right (HCC) 4/2012 Initial Diagnosis Malignant Neoplasm Of Breast Female Right (HCC) April 2012: Palpable lump in right breast, core biopsy showed invasive ductal carcinoma with associated DCIS with comedo necrosis ER (92%)/PR positive (22%)/ HER2/Neu. Ki-46% May 2012: right breast lumpectomy. Final pathology showed 1.5 cm invasive ductal carcinoma, grade 3, 3/3 sentinel lymph node biopsy negative. Oncotype DX -high risk risk of recurrence 29%. May 2012-January 2014: Adjuvant ACT for a total of six cycles finished in October 2012. Adjuvant radiation completed in January 2013 when she started taking anastrozole, which was self- discontinued in January 2014 secondary to arthralgias 5/2/2022 Biopsy/Pathology Lymph node, 4R, EBUS FNA: metastatic adenocarcinoma; origin likely mammary I will be investing in your company because I believe we need more research for cancer and I don't want anyone to have to go through this chemo treatment. Please respond to this comment. Thank you, Ellen
Show more
3
0
Ellen Hanson
3 years ago
Is there any way, if I invest that I could be a participant in the clinic trials for TargaZyme??? This is my current status: 5/17/2022 Clinical Stage Staging form: Corpus Uteri - Carcinoma And Carcinosarcoma, AJCC 8th Edition - Clinical stage from 5/17/2022: FIGO Stage IA (cT1a, cN0(sn), cM0) Histopathologic type: Clear cell adenocarcinoma, NOS Stage prefix: Initial diagnosis Method of lymph node assessment: Sentinel lymph node biopsy Histologic grade (G): G3 Histologic grading system: 3 grade system Depth of myometrial invasion (mm): 5 Pelvic nodal status: Negative Malignant Neoplasm Of Breast Female Right (HCC) 4/2012 Initial Diagnosis Malignant Neoplasm Of Breast Female Right (HCC) April 2012: Palpable lump in right breast, core biopsy showed invasive ductal carcinoma with associated DCIS with comedo necrosis ER (92%)/PR positive (22%)/ HER2/Neu. Ki-46% May 2012: right breast lumpectomy. Final pathology showed 1.5 cm invasive ductal carcinoma, grade 3, 3/3 sentinel lymph node biopsy negative. Oncotype DX -high risk risk of recurrence 29%. May 2012-January 2014: Adjuvant ACT for a total of six cycles finished in October 2012. Adjuvant radiation completed in January 2013 when she started taking anastrozole, which was self- discontinued in January 2014 secondary to arthralgias 5/2/2022 Biopsy/Pathology Lymph node, 4R, EBUS FNA: metastatic adenocarcinoma; origin likely mammary I will be investing in your company because I believe we need more research for cancer and I don't want anyone to have to go through this chemo treatment. Please respond to this comment. Thank you, Ellen
Show more
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
W Kim Colich
3 years ago
Hi Lynnet, A month has now passed since I first wrote and there are less than 50 investors, and less than $40K raised - which is less than 4% of your targeted goal. Now with only 3 weeks left in your raise, perhaps you might reconsider lowering the minimum investment amount back down to your original $304.52, or at least no more than $331.00 (50 shares). Please extend your raise and make your campaign more accessible and inviting to the small investor. And please do take this "advice into consideration". Thanks for listening. Blessings
Show more
0
0